Therapy News and Research

RSS

INF2 gene mutation is a major cause for focal segmental glomerulosclerosis

Mutations in a gene called INF2 are by far the most common cause of a dominantly inherited condition that leads to kidney failure, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology. The results may help with screening, prevention, and therapy.

21 Jan 2011

Major breakthrough: Genome-based medicine for treatment of alcoholism

For the first time in alcohol addiction research, UVA investigators have successfully treated alcohol-dependent individuals with medication that is tailored specifically to match their genetic profile.

21 Jan 2011

NeoStem completes merger with Progenitor Cell Therapy

NeoStem, Inc. and Progenitor Cell Therapy LLC announced today the closing of their previously announced merger transaction.

21 Jan 2011

ACT Biotech releases telatinib Phase 2 trial data for metastatic stomach cancer

ACT Biotech, a biopharmaceutical company focused on the development of highly targeted, oral therapeutics for the treatment of cancer, today released data on additional analysis of the Phase 2 clinical trial of telatinib in patients with metastatic stomach cancer that further supports the highly-potent nature of the antiangiogenic agent.

21 Jan 2011

Scientists decipher genetic code for a pancreatic cancer type

Scientists at Johns Hopkins have deciphered the genetic code for a type of pancreatic cancer, called neuroendocrine or islet cell tumors. The work, described online in the Jan. 20 issue of Science Express, shows that patients whose tumors have certain coding "mistakes" live twice as long as those without them.

21 Jan 2011

PROSPECT trial results shed new light on plaque types that cause unexpected heart attacks

Results from the PROSPECT clinical trial shed new light on the types of vulnerable plaque that are most likely to cause sudden, unexpected adverse cardiac events, and on the ability to identify them through imaging techniques before they occur.

21 Jan 2011

COPD patients on LTOT may face high risk of death from cardiovascular disease

Patients suffering from chronic obstructive pulmonary disease who are on long-term oxygen therapy have more to worry about than breathing difficulties. According to a new study by researchers in Sweden, COPD patients on LTOT today face an increased risk of death from cardiovascular disease and other non-respiratory ailments.

20 Jan 2011

Semen allergy to one's own

According to a study from Dutch researchers, some men are allergic to their own semen, developing a mysterious flu-like illness after they have an ejaculation. The condition, known as post-orgasmic illness syndrome or POIS, has been documented since 2002. It manifests as feverishness, runny nose, extreme fatigue and burning eyes, which can last for up to a week.

20 Jan 2011

FDA accepts Vertex's telaprevir NDA for six-month Priority Review

Vertex Pharmaceuticals Incorporated announced today that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for telaprevir and granted the company's request for six-month Priority Review. Telaprevir is Vertex's lead medicine in development for people with genotype 1 chronic hepatitis C.

20 Jan 2011

Grayscale IVUS and VH IVUS tissue characterization software help accurate assessment of blockage risk

Volcano Corporation today announced the publication of results from the PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) study in The New England Journal of Medicine showing that grayscale intravascular ultrasound (IVUS) and Volcano's proprietary VH® IVUS tissue characterization software enable physicians to more accurately assess the risk of individual blockages than the use of the current standard-of-care-- angiographic imaging-- alone.

20 Jan 2011

Genetic expression can be modified with natural substances to prevent chronic illness

Research findings demonstrating how genetic expression can be modified with natural substances to prevent chronic illness was the topic of an address by Jeffrey Bland, Ph.D., FACN, FACB, at the 8th Annual Scripps Center for Integrative Medicine 2011 conference in San Diego, California, January 13 - 16.

20 Jan 2011

Clinical Immunology Research Laboratory at The Mount Sinai Medical Center receives Octapharma grant

Octapharma USA today announced the second grant recipient of the Octapharma 25th Anniversary Grants Program is the Clinical Immunology Research Laboratory at The Mount Sinai Medical Center. The Octapharma Grants program supports clinical or pre-clinical research focused on human protein therapies in hematology, immune therapy, intensive care and emergency medicine.

20 Jan 2011

Breastfeeding can partially offset long-term side effects of cancer treatment

Women who have survived childhood cancer should be advised to breastfeed if they can, in order to offset some of the negative health effects of their earlier cancer treatment. According to Susan Ogg and colleagues from St. Jude Children's Research Hospital in Memphis, Tennessee, making women aware of the benefits of breastfeeding should be part of routine post-cancer diet and healthy lifestyle recommendations.

20 Jan 2011

HIV-infected patients three times more likely to suffer strokes

While the overall hospitalization rate for stroke has declined in recent years, the numbers have jumped dramatically for patients infected with human immunodeficiency virus (HIV), suggesting they may be up to three times more likely to suffer a stroke than people uninfected by the virus that causes AIDS.

20 Jan 2011

NMDP selects Velos to supply new Product Fulfillment and CDR System

The National Marrow Donor Program announced today that it has selected Velos, a leading California health care software provider, to supply its new Product Fulfillment and Clinical Data Repository System.

20 Jan 2011

ISCT launches commercial development focus group addressing Cell Therapies for Peripheral Vascular Disease

In keeping with its commitment to connect industry, regulatory experts, therapeutic societies and translational centers to advance emerging cellular therapies, ISCT announces its first commercial development focus group addressing Cell Therapies for Peripheral Vascular Disease (PVD).

20 Jan 2011

Ultrasound device shows promise in breaking up pulmonary embolisms: Research

A tiny ultrasound device that helps dissolve blood clots is showing promise in breaking up potentially deadly pulmonary embolisms, blockages of blood vessels in the lungs that can occur after long plane rides, surgery and extended bed rest.

20 Jan 2011

FOLOTYN Phase 2 peripheral T-cell lymphoma study results published in Journal of Clinical Oncology

Allos Therapeutics, Inc. today announced that the Journal of Clinical Oncology has published data from the Company's pivotal Phase 2 PROPEL study demonstrating clinical activity of FOLOTYN® (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

20 Jan 2011

Pervasis pursues matrix-embedded endothelial cell-based therapy to target and regulate cell stroma

Pervasis Therapeutics, Inc. today announced that the company is pursuing a matrix-embedded endothelial cell-based therapy (PVS-30200) to target and regulate cell stroma (the tumor environment or "ecosystem" that is comprised of various supporting cell types distinct from cancer cells) in order to prevent key processes that play a role in advancing solid tumor growth and metastasis.

20 Jan 2011

U.S. Physical Therapy launches Fit2WRK to provide solutions for prevention of injuries in workplace

U.S. Physical Therapy, a national operator of outpatient physical therapy clinics, announced that it has successfully launched a workers compensation and disability initiative called Fit2WRK. Fit2WRK provides an integrated solution for the management and prevention of injuries in the workplace.

20 Jan 2011

Therapy News and Research

INF2 gene mutation is a major cause for focal segmental glomerulosclerosis

Major breakthrough: Genome-based medicine for treatment of alcoholism

NeoStem completes merger with Progenitor Cell Therapy

ACT Biotech releases telatinib Phase 2 trial data for metastatic stomach cancer

Scientists decipher genetic code for a pancreatic cancer type

PROSPECT trial results shed new light on plaque types that cause unexpected heart attacks

COPD patients on LTOT may face high risk of death from cardiovascular disease

Semen allergy to one's own

FDA accepts Vertex's telaprevir NDA for six-month Priority Review

Grayscale IVUS and VH IVUS tissue characterization software help accurate assessment of blockage risk

Genetic expression can be modified with natural substances to prevent chronic illness

Clinical Immunology Research Laboratory at The Mount Sinai Medical Center receives Octapharma grant

Breastfeeding can partially offset long-term side effects of cancer treatment

HIV-infected patients three times more likely to suffer strokes

NMDP selects Velos to supply new Product Fulfillment and CDR System

ISCT launches commercial development focus group addressing Cell Therapies for Peripheral Vascular Disease

Ultrasound device shows promise in breaking up pulmonary embolisms: Research

FOLOTYN Phase 2 peripheral T-cell lymphoma study results published in Journal of Clinical Oncology

Pervasis pursues matrix-embedded endothelial cell-based therapy to target and regulate cell stroma

U.S. Physical Therapy launches Fit2WRK to provide solutions for prevention of injuries in workplace

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News